Regucalcin

Masayoshi Yamaguchi, Ph.D., IOM, FAOE, DDG, DG, is Adjunct Professor, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA (2013 - ). Dr. Yamaguchi is engaged in the fields of endocrinology and cell signaling since 1971, and these researches are developed in the aspect of biochemistry, molecular biology, endocrinology, metabolism, nutrition, pharmacology, and toxicology. Dr Yamaguchi has an interesting for cell signaling mechanism, bone biology, nutritional factor and osteoporosis prevention, diabetes and diabetic osteoporosis, cancer biology, and cancer cell bone metastasis. Dr. Yamaguchi discovered two novel proteins and genes; cell signaling suppressor protein (named regucalcin; 1978) and transcriptional factor RGPR-p117 (regucalcin gene promoter region-related protein; 2001). Dr Yamaguchi generated regucalcin transgenic rats, which were registered as international patents including USA, EU and Japan, and this animal was found to induce osteoporosis and hyperlipidemia. Moreover, Dr. Yamaguchi proposed the potential role of regucalcin as a key suppressor protein in carcinogenesis. Thus far, Dr Yamaguchi published over 550 English articles to professional journals with peer-review, and registered over 20 national and international patents.

PrefaceStructure of Regucalcin Gene and ProteinThe Horizons of Regucalcin in Male ReproductionRegucalcin: A Tumor-Associated Antigen and a Tumor-Suppressing MoleculeThe Role of Regucalcin in Bone Remodeling and OsteoporosisInvolvement of Regucalcin in Diabetes and HyperlipedemiaExtracellular Vesicles: A Conversation in the BodyIndex.